Literature DB >> 7694515

CD34 and factor XIIIa in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans.

P Abenoza1, T Lillemoe.   

Abstract

To assess the use of anti-CD34 and anti-factor-XIIIa antibodies for the differential diagnosis of dermatofibroma (DF) and dermatofibrosarcoma protuberans (DFSP), we stained 40 DFs and 13 DFSPs. A significant population of dendritic and spindle cells was reactive with anti-factor-XIIIa in 90% of DFs. In DFSP, most cases had very few or no reactive cells for this antiserum and reactivity was confined to the infiltrating edges of the neoplasm or to a very low percentage of cells within the bulk of the tumor. A significant overlap was detected, a reason why the stain is useful but lacks absolute specificity for this purpose. Human progenitor cell antigen (CD34) was found in all cases of DFSP that had 50-100% of reactive cells, but in only five DFs. In DFs, the reactivity for CD34 was focal, with only < or = 20% positive cells. When used together with other histopathological criteria, factor-XIIIa antibody and particularly CD34 may help to differentiate these two processes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7694515     DOI: 10.1097/00000372-199310000-00003

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  20 in total

1.  Immunoblot analysis of CD34 expression in histologically diverse neoplasms.

Authors:  Y Natkunam; R V Rouse; S Zhu; C Fisher; M van De Rijn
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

2.  Dermatofibrosarcoma protuberans: Our experience of 59 cases.

Authors:  Alessio Stivala; Giuseppe A G Lombardo; Gianluca Pompili; Maria Stella Tarico; Filippo Fraggetta; Rosario Emanuele Perrotta
Journal:  Oncol Lett       Date:  2012-08-30       Impact factor: 2.967

3.  Imaging findings of head and neck dermatofibrosarcoma protuberans.

Authors:  G G Millare; N Guha-Thakurta; E M Sturgis; A K El-Naggar; J M Debnam
Journal:  AJNR Am J Neuroradiol       Date:  2013-08-01       Impact factor: 3.825

4.  Dermatofibrosarcoma protuberans: review of 20-years experience.

Authors:  Jaime Ruiz-Tovar; Montserrat Fernández Guarino; María Eugenia Reguero Callejas; Asunción Aguilera Velardo; Juan Arano Bermejo; Luis Cabañas Navarro
Journal:  Clin Transl Oncol       Date:  2006-08       Impact factor: 3.405

5.  Dermatofibrosarcoma protuberans: a case report and review of the literature.

Authors:  Sanjay Bhambri; Avani Desai; James Q Del Rosso; Narciss Mobini
Journal:  J Clin Aesthet Dermatol       Date:  2008-05

6.  A practical and comprehensive immunohistochemical approach to the diagnosis of superficial soft tissue tumors.

Authors:  Wael Al-Daraji; Ehab Husain; Bettena G Zelger; Bernhard Zelger
Journal:  Int J Clin Exp Pathol       Date:  2008-06-10

7.  Magnetic resonance imaging and mammographic appearance of dermatofibrosarcoma protuberans in a male breast: a case report and literature review.

Authors:  Xin Chen; Yung Hsin Chen; Yi-Li Zhang; You-Min Guo; Zhi-Lan Bai; Xian Zhao
Journal:  J Med Case Rep       Date:  2009-06-16

Review 8.  Current treatment options in dermatofibrosarcoma protuberans.

Authors:  Doreen Lemm; L-O Mügge; T Mentzel; K Höffken
Journal:  J Cancer Res Clin Oncol       Date:  2009-02-10       Impact factor: 4.553

9.  PDGFB RNA in situ hybridization for the diagnosis of dermatofibrosarcoma protuberans.

Authors:  Jeffrey M Cloutier; Grace Allard; Gregory R Bean; Jason L Hornick; Gregory W Charville
Journal:  Mod Pathol       Date:  2021-03-24       Impact factor: 7.842

10.  Myxoinflammatory fibroblastic sarcoma: an immunohistochemical and molecular genetic study of 73 cases.

Authors:  David Suster; Michael Michal; Huiya Huang; Shira Ronen; Stephanie Springborn; Maria Debiec-Rychter; Steven D Billings; John R Goldblum; Brian P Rubin; Michal Michal; Saul Suster; A Craig Mackinnon
Journal:  Mod Pathol       Date:  2020-06-08       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.